Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group

Federica Grosso, Lorenzo D’Ambrosio, Massimo Zucchetti, Toni Ibrahim, Stefano Tamberi, Cristina Matteo, Eliana Rulli, Danila Comandini, Emanuela Palmerini, Giacomo Giulio Baldi,

Cancer · 2020 · 25 citations · 25 references

Concepts

Abstract

Background Although elderly patients (≥70 years) represent 30% of new diagnoses of soft tissue sarcoma (STS), they are underrepresented in clinical trials and are often unfit to receive standard anthracycline‐based chemotherapy. Trabectedin is registered as a second‐line treatment for advanced STS and is characterized by a favorable safety profile. Methods The aim of this single‐arm, phase 2 study was to investigate trabectedin (scheduled dose, 1.3‐1.5 mg/m 2 ) as a first‐line treatment in elderly patients with advanced stage STS who are inoperable and are unfit to receive standard anthracycline‐based chemotherapy. The coprimary endpoints were progression‐free survival at 3 months (PFS3) and the rate of clinically limiting toxicities (CLTs). We also conducted an ancillary study on pharmacokinetics. Results Twenty‐four patients (12 men and 12 women) with a median age of 79 years (interquartile range [IQR], 74‐83 years) were enrolled. The histological subtype was leiomyosarcoma in 46%, liposarcoma in 33%, and other histotypes in 21%. The median number of trabectedin courses was 4 (IQR, 3‐6), with 7 patients (29%) receiving ≥6 cycles. Eight patients (33%) required dose reductions. The most frequent grade 3/4 adverse events were neutropenia in 9 patients (38%), fatigue in 5 patients (21%), and aminotransferase elevation in 5 patients (21%). PFS3, median PFS, and overall survival were 71% (80% CI, 57%‐81%), 4 months, and 12 months, respectively. Ten patients (42% [80% CI, 28%‐57%]) experienced CLTs. Trabectedin C max , half‐life, clearance, and distribution volume were 1.28 ng/mL (standard deviation [SD], 0.58 ng/mL), 26.70 hours (SD, 9.09 hours), 39.98 L/h/m 2 (SD, 14.08 L/h/m 2 ), and 1460 L/m 2 (SD, 561 L/m 2 ), respectively. Conclusion Trabectedin can be administered safely to elderly patients with STS who are unfit to receive anthracyclines. Pharmacokinetics in the elderly population was superimposable to historical data.

References

25